{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T20:26:07Z","timestamp":1773951967288,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.prro.2021.07.006","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T11:41:29Z","timestamp":1631533289000},"page":"e34-e39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Stereotactic Ablative Radiation Therapy for the Treatment of Upper Urinary Tract Urothelial Carcinoma"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6472-679X","authenticated-orcid":false,"given":"Julia","family":"Khriguian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Horacio","family":"Patrocinio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sero","family":"Andonian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armen","family":"Aprikian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wassim","family":"Kassouf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Tanguay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio L.","family":"Cury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prro.2021.07.006_bib0001","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00345-012-0877-2","article-title":"Upper urinary tract urothelial cell carcinoma: Location as a predictive factor for concomitant bladder carcinoma","volume":"31","author":"Cosentino","year":"2013","journal-title":"World J Urol"},{"key":"10.1016\/j.prro.2021.07.006_bib0002","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.urology.2006.09.065","article-title":"Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma","volume":"69","author":"Raman","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.prro.2021.07.006_bib0003","first-page":"9699","article-title":"Outcomes of upper tract urothelial cancer managed non-surgically","volume":"26","author":"Syed","year":"2019","journal-title":"Can J Urol"},{"key":"10.1016\/j.prro.2021.07.006_bib0004","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): A randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.prro.2021.07.006_bib0005","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.ijrobp.2020.06.014","article-title":"Stereotactic ablative radiotherapy for \u2265T1b primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK)","volume":"108","author":"Siva","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2021.07.006_bib0006","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","article-title":"Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline","volume":"158","author":"Stevens","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.prro.2021.07.006_bib0007","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.prro.2021.07.006_bib0008","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.semradonc.2008.04.001","article-title":"An overview of hypofractionation and introduction to this issue of Seminars in Radiation Oncology","volume":"18","author":"Timmerman","year":"2008","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.prro.2021.07.006_bib0009","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13014-018-1001-6","article-title":"Stereotactic ablative radiotherapy for ultra-central lung tumors: Prioritize target coverage or organs at risk?","volume":"13","author":"Murrell","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.prro.2021.07.006_bib0010","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.prro.2021.07.006_bib0011","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eururo.2020.05.042","article-title":"European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2020 update","volume":"79","author":"Roupret","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2021.07.006_bib0012","unstructured":"National Comprehensive Cancer Network. Bladder cancer, version 6.2020. Available at: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1417. Accessed October 29, 2021."},{"key":"10.1016\/j.prro.2021.07.006_bib0013","doi-asserted-by":"crossref","first-page":"526","DOI":"10.4103\/0970-1591.44262","article-title":"Ureteroscopic management of upper tract transitional cell carcinoma and ureteropelvic obstruction","volume":"24","author":"Crouzet","year":"2008","journal-title":"Indian J Urol"},{"key":"10.1016\/j.prro.2021.07.006_bib0014","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.urolonc.2019.05.021","article-title":"The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma: A systematic review","volume":"37","author":"Iwata","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.prro.2021.07.006_bib0015","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.ijrobp.2019.03.027","article-title":"Adjuvant treatments for advanced stage, non-metastatic upper tract urothelial carcinoma: A multicenter study","volume":"104","author":"Kim","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2021.07.006_bib0016","first-page":"333","article-title":"Adjuvant radiotherapy for stage III\/IV urothelial carcinoma of the upper tract","volume":"34","author":"Jwa","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.prro.2021.07.006_bib0017","doi-asserted-by":"crossref","first-page":"38175","DOI":"10.1038\/srep38175","article-title":"Adjuvant radiotherapy for locally advanced upper tract urothelial carcinoma","volume":"6","author":"Huang","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.prro.2021.07.006_bib0018","first-page":"247","article-title":"Adjuvant and salvage radiotherapy for urothelial cell carcinoma of the upper urinary tract: Experience in a single institution","volume":"35","author":"Fan","year":"2012","journal-title":"Chang Gung Med J"},{"key":"10.1016\/j.prro.2021.07.006_bib0019","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12957-020-01877-w","article-title":"Pattern and risk factors of local recurrence after nephroureterectomy for upper tract urothelial carcinoma","volume":"18","author":"Li","year":"2020","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.prro.2021.07.006_bib0020","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/JU.0000000000000644","article-title":"Phase II trial of neoadjuvant systemic chemotherapy followed by extirpative surgery in patients with high grade upper tract urothelial carcinoma","volume":"203","author":"Margulis","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.prro.2021.07.006_bib0021","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1200\/JCO.2016.69.4141","article-title":"Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and\/or positive regional lymph node upper tract urothelial carcinoma","volume":"35","author":"Seisen","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2021.07.006_bib0022","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ctrv.2018.06.002","article-title":"Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies","volume":"68","author":"Massari","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.prro.2021.07.006_bib0023","article-title":"Stereotactic body radiotherapy for localized ureter transitional cell carcinoma: Three case reports","volume":"2015","author":"Maehata","year":"2015","journal-title":"Case Rep Urol"},{"key":"10.1016\/j.prro.2021.07.006_bib0024","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.juro.2014.08.044","article-title":"Single fraction radiosurgery for the treatment of renal tumors","volume":"193","author":"Staehler","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.prro.2021.07.006_bib0025","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cncr.24135","article-title":"Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration","volume":"115","author":"Margulis","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.prro.2021.07.006_bib0026","first-page":"2","article-title":"European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. European Association of Urology Guideline Group for urothelial cell carcinoma of the upper urinary tract","volume":"36","author":"Roupret","year":"2012","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.prro.2021.07.006_bib0027","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.eururo.2012.02.042","article-title":"Multifocal carcinoma in situ of the upper tract is associated with high risk of bladder cancer recurrence","volume":"61","author":"Xylinas","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2021.07.006_bib0028","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.urolonc.2020.01.008","article-title":"Synchronous and metachronous urothelial carcinoma of the upper urinary tract and the bladder: Are they clonally related? A systematic review","volume":"38","author":"van Doeveren","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.prro.2021.07.006_bib0029","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1016\/j.juro.2012.08.017","article-title":"Upper urinary tract recurrence following radical cystectomy for bladder cancer: A meta-analysis on 13,185 patients","volume":"188","author":"Picozzi","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.prro.2021.07.006_bib0030","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12967-017-1251-3","article-title":"A phase I\/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: Evaluation of safety and clinical and immunologic response","volume":"15","author":"Sundahl","year":"2017","journal-title":"J Transl Med"},{"key":"10.1016\/j.prro.2021.07.006_bib0031","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.eururo.2019.01.009","article-title":"Randomized phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma","volume":"75","author":"Sundahl","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2021.07.006_bib0032","doi-asserted-by":"crossref","first-page":"S468","DOI":"10.21037\/jtd.2018.01.130","article-title":"Combining radiation plus immunotherapy to improve systemic immune response","volume":"10","author":"Cushman","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.prro.2021.07.006_bib0033","first-page":"65","article-title":"Radiotherapy combination opportunities leveraging immunity for the next oncology practice","volume":"67","author":"Herrera","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.prro.2021.07.006_bib0034","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): A multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2021.07.006_bib0035","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1200\/JCO.19.01213","article-title":"Long-term outcomes in KEYNOTE-052: Phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer","volume":"38","author":"Vuky","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2021.07.006_bib0036","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): A multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850021002290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850021002290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:23:36Z","timestamp":1761819816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850021002290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1879850021002290"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2021.07.006","relation":{},"ISSN":["1879-8500"],"issn-type":[{"value":"1879-8500","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic Ablative Radiation Therapy for the Treatment of Upper Urinary Tract Urothelial Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2021.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}